Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval
Odronextamab Was Filed For FL And DLBCL
The company received two complete response letters from the US FDA for the CD20xCD3 bispecific antibody odronextamab due to clinical trial requirements for accelerated approval.
